ArriVent Biopharma

Q2 FY2026 EarningsQ2 FY2026 results missed consensus on the bottom line, with a GAAP EPS loss of $1.05 versus the $0.99 expected. Operating loss reached $52.7M, exceeding the $47.7M consensus due to higher-than-anticipated R&D and G&A expenses. However, the company maintains a robust cash position of $373.1M, extending its runway into 2028, with high-impact Phase 3 topline data for firmonertinib expected in 2H 2026.